Although several studies [10, 11, 31] have reported the elevated platelet counts in younger CML patients, very little is known about the association of increased platelet counts and mutations in ASXL1. Behrens et al. [27] has reported that pediatric CML patients harboring pathogenic ASXL1 mutations at diagnosis exhibited higher counts of leukocytes and platelets compared to patients without any mutation or other mutation than ASXL1, which may be a potential consequence of the relative increase in proliferative capacity in the study cohort. This evidence concerns the gene ASXL1 and chronic myelogenous leukemia, BCR-ABL1 positive.